GlassScriptPhysician profile
Moshe Szlechter
NPI 1750494829
$2,580.38
in general payments reported to CMS, 2019-2025
19 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $174 · 2021: $303 · 2022: $209 · 2023: $344 · 2024: $611 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $510.48 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $280.10 | 2023-2025 | Stellaris, Xiidra, Vyzulta |
| Alcon Vision LLC | $258.37 | 2024-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Abbvie INC. | $206.96 | 2023-2024 | Lumigan, Durysta |
| Dompe US, INC. | $190.39 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $172.10 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $136.31 | 2021-2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Eylea |
| Tarsus Pharmaceuticals, INC. | $107.92 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $84.61 | 2022-2025 | |
| Biotissue Holdings INC. | $73.14 | 2023-2024 | |
| Astellas Pharma US INC | $70.74 | 2023-2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $67.58 | 2021-2022 | |
| Oyster Point Pharma, INC. | $59.50 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.53 | 2019-2020 | |
| Genentech USA, INC. | $29.67 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $16.58 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Szlechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.